UK markets closed
NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.75 +0.73 (+0.94%) GOLD FUTURES
2,391.10 +31.20 (+1.32%) DOW
39,840.70 +282.59 (+0.71%) Bitcoin GBP
51,563.18 +3,160.63 (+6.53%)
GILD May 2024 66.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:50PM EDT. Market open.
| Previous close | 1.8700 |
| Open | 1.8800 |
| Bid | 1.8900 |
| Ask | 1.9600 |
| Strike | 66.00 |
| Expiry date | 2024-05-24 |
| Day's range | 1.8800 - 2.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | 158 |
Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
© 2024 Yahoo. All rights reserved.